<DOC>
	<DOC>NCT00670488</DOC>
	<brief_summary>Treatment of patients with locally advanced or metastatic solid tumors who have failed standard therapy or no other standard therapy exists.</brief_summary>
	<brief_title>Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patient must have confirmed locally advanced or metastatic solid tumors that have failed to respond to standard therapy, have gotten worse or have come back after existing therapy Has normal organ function; is no greater than 2 on the ECOG Performance Scale Has a negative blood or urine pregnancy test within 72 hours of receiving the first dose of study drug if patient is female Is able to swallow capsules and has no surgical or bodily condition that will prevent the patient from swallowing and absorbing oral medications on an ongoing basis Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4 weeks of starting the study and has not recovered from adverse events caused by the treatment Is currently participating or has participated in a study with an investigational compound or device within 30 days Has a primary central nervous system tumor Has a history or current evidence of heart disease, slow heart rate or untreated high blood pressure Is a known diabetic who is taking insulin or oral antidiabetic therapy Is pregnant or breastfeeding or planning to become pregnant during the study Is HIVpositive Has known history of Hepatitis B or C or active Hepatitis A Is receiving treatment with oral corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>